Inventor
William C. Olson
Inventor
Yorktown Heights, NY, US
Overview
Patents· 49 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
C07KPeptides31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C12NMicroorganisms or enzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
Y02ATechnologies for adaptation to climate change2%
C07JSteroids1%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
PatentTitleYear
11,117,955Anti-Zika virus antibodies and methods of use202110,844,137Anti-CTLA-4 antibodies and uses thereof202010,829,544Human antibodies to Ebola virus glycoprotein202010,806,780Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof202010,787,501Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments202010,736,976Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging202010,730,944Anti-CD8 antibodies and uses thereof202010,711,032Steroids and protein-conjugates thereof202010,689,436Human antibodies to influenza hemagglutinin202010,633,434Anti-C5 antibodies202010,501,526Human antibodies to Ebola virus glycoprotein201910,500,274Methods for reducing viral load in HIV-1 infected patients201910,463,748Human antibodies to 201910,421,804Anti-Zika virus antibodies and methods of use201910,392,432Human antibodies to influenza hemagglutinin201910,081,670Human antibodies to Ebola virus glycoprotein20189,771,414'Human antibodies to ebola virus glycoprotein'20179,695,248'PSMA antibodies and uses thereof'20179,545,451'Anti-PRLR antibodies and methods for killing PRLR-expressing cells'20179,242,012'Methods for killing PSMA-expressing, taxane-resistant cancer cells'20168,986,697'Antibodies for the treatment of Clostridium difficile-associated infection and disease'20158,821,877'Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist'20148,470,330'PSMA antibodies and uses thereof'20138,114,965'Compositions of PSMA antibodies'20127,939,083'Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain'20117,935,797'CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion'20117,858,298'Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists'20107,850,971'PSMA antibodies and protein multimers'20107,851,600'Anti-CCR5 antibody'20107,736,649'Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors'20107,666,419'Anti-CCR5 antibody'20107,592,014'Stabilized viral envelope proteins and uses thereof'20097,479,553'Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins'20097,446,177'Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection'20087,138,119'Compositions and methods for inhibition of HIV-1 infection'20067,122,185'Anti-CCR5 antibody'20067,060,273'Methods for inhibiting HIV-1 infection'20067,037,497'Methods for inhibiting HIV-1 infection'20067,022,324'Stabilized viral envelope proteins and uses thereof'20067,022,323'Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection'20066,908,734'Sulfated CCR5 peptides for HIV-1 infection'20056,710,173'Stabilized viral envelope proteins and uses thereof'20046,692,745'Compositions and methods for inhibition of HIV-1 infection'20046,605,644'Analgesic regimen'20036,548,636'Sulfated CCR5 peptides for HIV-1 infection'20036,344,545'Method for preventing HIV-1 infection of CD4 cells'20026,339,105'Analgesic regimen'20026,107,019'Method for preventing HIV-1 infection of CD4.sup.+ cells'20005,003,047'Method for purifying biologically active ligate'1991Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1991Based in Brookline, MA, US· patent location history
2000–2015Patents assigned to PROGENICS PHARM INC (19)· patent assignee history
2000–2014Based in Ossining, NY, US· patent location history
2002–2003Based in Princeton, NJ, US· patent location history
2010–2017Patents assigned to PSMA DEV COMPANY LLC (5)· patent assignee history
2011–2021Based in Yorktown Heights, NY, US· patent location history
2012–2017Patents assigned to OLSON WILLIAM C (6)· patent assignee history
2012–2017Patents assigned to MA DANGSHE (5)· patent assignee history
2017–2021Patents assigned to REGENERON PHARMA (17)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| PROGENICS PHARM INC | 19 | 2000–2015 |
| REGENERON PHARMA | 17 | 2017–2021 |
| OLSON WILLIAM Cself | 6 | 2012–2017 |
| MA DANGSHE | 5 | 2012–2017 |
| PSMA DEV COMPANY LLC | 5 | 2010–2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| Yorktown Heights, New York, US | 23 | 2011–2021 |
| Ossining, New York, US | 23 | 2000–2014 |
| Princeton, New Jersey, US | 2 | 2002–2003 |
| Brookline, Massachusetts, US | 1 | 1991 |